The cellular composition of lymph nodes in the earliest phase of inflammatory arthritis

Annals of the Rheumatic Diseases

Volumn 72, Issue 8, 2013, Pages 1420-1424

  Van Baarsen, L G M ^a   De Hair, M J H ^a   Ramwadhdoebe, T H ^a   Zijlstra, I J A J ^a   Maas, M ^a   Gerlag, D M ^a   Tak, P P ^a,b,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD19 ANTIGEN; CD69 ANTIGEN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN M; RHEUMATOID FACTOR;

ADULT; ARTICLE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE SUBPOPULATION; CELL COMPOSITION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSTIMULATION; INGUINAL LYMPH NODE; LYMPH NODE BIOPSY; LYMPHOCYTE SUBPOPULATION; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

B CELLS; EARLY RHEUMATOID ARTHRITIS; T CELLS;

ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; B-LYMPHOCYTE SUBSETS; CD8-POSITIVE T-LYMPHOCYTES; EARLY DIAGNOSIS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN M; IMMUNOPHENOTYPING; LECTINS, C-TYPE; LYMPH NODES; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; T-LYMPHOCYTE SUBSETS;

EID: 84880136894     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202990     Document Type: Article

References (20)

1. Quinn MA, Conaghan PG, Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence? Rheumatology (Oxford) 2001;40:1211-20.
2. Mottonen T, Hannonen P, Korpela M, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002;46:894-8. (Pubitemid 34303799)
3. O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002;46:283-5. (Pubitemid 34136564)
4. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6. (Pubitemid 38198821)
5. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9. (Pubitemid 37280601)
6. Aho K, Palosuo T, Raunio V, et al. When does rheumatoid disease start? Arthritis Rheum 1985;28:485-9. (Pubitemid 15109897)
7. Aho K, von ER, Kurki P, et al. Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J Rheumatol 1993;20:1278-81. (Pubitemid 23310975)
8. Jorgensen KT, Wiik A, Pedersen M, et al. Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors. Ann Rheum Dis 2008;67:860-6. (Pubitemid 351829389)
9. Bos WH, Wolbink GJ, Boers M, et al. Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis 2010;69:490-4.
10. Gerlag DM, Raza K, van Baarsen LG, et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis 2012;71:638-41.
11. van de Sande MG, de Hair MJ, van der Leij C, et al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis 2011;70:772-7.
12. Li J, Kuzin I, Moshkani S, et al. Expanded CD23(+)/CD21(hi) B cells in inflamed lymph nodes are associated with the onset of inflammatory-erosive arthritis in TNF-transgenic mice and are targets of anti-CD20 therapy. J Immunol 2010;184:6142-50.
13. Rodriguez-Palmero M, Pelegri C, Ferri MJ, et al. Alterations of lymphocyte populations in lymph nodes but not in spleen during the latency period of adjuvant arthritis. Inflammation 1999;23:153-65. (Pubitemid 29178603)
14. Wooley PH, Whalen JD. Pristane-induced arthritis in mice. III. Lymphocyte phenotypic and functional abnormalities precede the development of pristane-induced arthritis. Cell Immunol 1991;138:251-9.
15. de Hair MJ, Zijlstra IA, boumans MJ, et al. Hunting for the pathogenesis of rheumatoid arthritis: core-needle biopsy of inguinal lymph nodes as a new research tool. Ann Rheum Dis 2012;71:1911-2.
16. Schwab SR, Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 2007;8:1295-301. (Pubitemid 350131168)
17. Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis?: II. T cell-independent mechanisms from beginning to end. Arthritis Rheum 2002;46:298-308. (Pubitemid 34136567)
18. Fox DA. The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives. Arthritis Rheum 1997;40:598-609.
19. Cope AP. T cells in rheumatoid arthritis. Arthritis Res Ther 2008;10(Suppl 1):S1.
20. van Baarsen LG, Bos WH, Rustenburg F, et al. Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis. Arthritis Rheum 2010;62:694-704.